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Abstract
We investigated the role of common genetic variation in immune-related genes on breast cancer disease-free survival (DFS)
in Korean women. 107 breast cancer patients of the Seoul Breast Cancer Study (SEBCS) were selected for this study. A total
of 2,432 tag single nucleotide polymorphisms (SNPs) in 283 immune-related genes were genotyped with the GoldenGate
Oligonucleotide pool assay (OPA). A multivariate Cox-proportional hazard model and polygenic risk score model were used
to estimate the effects of SNPs on breast cancer prognosis. Harrell’s C index was calculated to estimate the predictive
accuracy of polygenic risk score model. Subsequently, an extended gene set enrichment analysis (GSEA-SNP) was
conducted to approximate the biological pathway. In addition, to confirm our results with current evidence, previous
studies were systematically reviewed. Sixty-two SNPs were statistically significant at p-value less than 0.05. The most
significant SNPs were rs1952438 in SOCS4 gene (hazard ratio (HR) = 11.99, 95% CI = 3.62–39.72, P= 4.84E-05), rs2289278 in
TSLP gene (HR= 4.25, 95% CI = 2.10–8.62, P= 5.99E-05) and rs2074724 in HGF gene (HR= 4.63, 95% CI = 2.18–9.87, P= 7.04E-
05). In the polygenic risk score model, the HR of women in the 3rd tertile was 6.78 (95% CI = 1.48–31.06) compared to
patients in the 1st tertile of polygenic risk score. Harrell’s C index was 0.813 with total patients and 0.924 in 4-fold cross
validation. In the pathway analysis, 18 pathways were significantly associated with breast cancer prognosis (P,0.1). The IL-
6R, IL-8, IL-10RB, IL-12A, and IL-12B was associated with the prognosis of cancer in data of both our study and a previous
study. Therefore, our results suggest that genetic polymorphisms in immune-related genes have relevance to breast cancer
prognosis among Korean women.
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Introduction
Cancer is a significant health problem in many parts of the
worldwide [1,2]. In Korea, the incidence rate of breast cancer was
ranked second and the mortality rate fifth in Korean women,
which steadily increased from 1983 to 2010 [3]. The etiology and
progression of breast cancer is a multiple-step process caused by
combining many factors which involve environmental, hormonal
and genetic factors [4,5]. We focused on genetic factors involved in
immune response which was known to play a role in breast cancer
prognosis.
The association of immune markers with breast cancer
prognosis were well known and the role as key factor of
microenvironment of tumor such as tumor suppressor or growth.
For example, high density of CD68 which is high-infiltration of
tumor-associated macrophages was related with poorer outcome
in node-negative breast cancer [6] and CD44 positive patients
showed longer overall survival and progression free survival than
CD44 negative patients [7]. In addition, cytokines produced by
various immune cells were known to modulate the transition from
the innate to the adaptive immune response, the activation of anti-
tumor cells, persistent oxidative stress, and the angiogenesis of
breast cancer [8–10]. The prognosis of breast cancer was also
known to be associated with single nucleotide polymorphisms
(SNPs) in the immune system related genes [11–14]. Those reports
described that genetic variants of toll-like receptor 4 (TLR4),
interleukin 12 (IL-12), interleukin 2 (IL-2), and interleukin 6 (IL-6)
were related with breast cancer prognosis. However, there have
been few studies that investigate the association between
comprehensive list of variants in the immunity-related genes and
the prognosis of breast cancer.
Given the findings that immune system is related with breast
cancer prognosis, we hypothesized that many genetic polymor-
phisms in immune related genes might be prognostic factor of
breast cancer recurrence. In this study, the role of common
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immune genetic variations to the disease free survival (DFS) of
breast cancer was investigated with the multivariate Cox-
proportional hazard model by individual variants, polygenic risk
score model, and an extended gene set enrichment analysis.
Additionally, a systematic review of previous literature that had
reported on the associations between variants of the immunity-
related genes and the prognosis of various cancers was done.
Materials and Methods
Study population
Among subjects of Seoul Breast Cancer Study (SEBCS), a
multicenter based case-control study recruiting between 2001 and
2007, the participants in this study were patients diagnosed with
histologically confirmed breast cancer in the Seoul National
University Hospital during 2002–2004. Based on the sample
availability and quality of DNA, 140 breast cancer patients were
successfully genotyped [15]. Among them, 107 patients were
included in the final analysis after excluding patients without
survival status or clinical information or been diagnosed as
metastatic breast cancer patients.
During recruitment, well-trained interviewers provided patients
with informed consent forms and collected information with a
structured questionnaire. Through abstracting the medical chart,
information on survival status, hormone receptor status, and TNM
stage [16] were obtained.
This study design was approved by the Committee on Human
Research of Seoul National University Hospital (IRB No. H-0503-
144-004).
Genotyping
Among 209 samples met the genotyping criteria (concentration
.7.5 ng/ul and total amount of DNA .750 ng), 140 cases were
successfully genotyped. 283 immune-related candidate genes were
composed of 190 innate immune-related genes in innate immune
oligonucleotide pool assay (OPA) chip and 93 adaptive immune-
related genes in Non-Hodgkin’s lymphoma (NHL) OPA chip as
described in previous study [15,17]. 2,432 Tags SNPs were
selected with SNP500 Cancer project database considering the site
from 20 kb upstream of the first site of transcription of a candidate
gene to 10 kb downstream of the end site of the last exon of the
candidate gene and genotyped. Among them, 461 SNPs were
excluded from the analysis because of low minor allele frequency
(MAF) (,3%) and deviation from Hardy-Weinberg Equilibrium
(HWE) (P,1024). Finally, a total of 1,971 SNPs in 279 immunity
genes were selected for the analysis.
Statistical method
A DFS was calculated from the date when patients underwent a
breast cancer operation to the date of last follow-up or recurrence,
such as loco-regional, distant, contralateral recurrence and death
from any causes. If patients had no evidence of recurrence, they
were censored at the last follow-up date or on June 30, 2011. The
median follow-up time was 4.87 years (range, 0.25–6.72 years).
Demographic data including age (,50 and $50), body mass
index (BMI) (,21.4 and $21.4), family history of breast cancer in
1st and 2nd relatives (no and yes), educational level (# middle
school, high school, and $ college or university), smoking status
(never and ever), alcohol consumption (never and ever), and
menopausal status (premenopausal and postmenopausal), and
clinicopathological data including estrogen receptor status (ER)
(positive and negative), progesterone receptor status (PR) (positive
and negative), and 7th AJCC TNM stage (I, II, and III) were
assessed for DFS with the log-rank test and univariate Cox-
proportional hazard model. Multivariate Cox-proportional hazard
model adjusted for age, ER status, PR status, and TNM stage (I,
II, and III) was used to calculate the hazard ratio (HR) and their
95% CI of the effect for each SNP on the DFS of breast cancer
Figure 1. Associations of the polygenic risk score on breast cancer disease free survival. Kaplan-Meier survival curve and estimated
hazard ratios (HRs) of breast cancer in groups defined by tertile derived from the polygenic risk scores of the 107 patients with all 62 SNPs.
doi:10.1371/journal.pone.0103593.g001
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based on additive genetic models. If SNPs were located in the
same candidate gene and these SNPs had a linkage disequilibrium
(LD) (r2.0.4), the most significantly associated SNP were selected.
To correct the multiple comparison, false discovery rate (FDR) p-
values were calculated with the Benjamin-Hochberg method [18].
For the polygenic risk score method, the polygenic risk score
was calculated by adding the number of risk alleles in each patient
based on individual SNP analyses and the patients were
categorized into tertiles of polygenic risk score [19]. HR and
95% confidence intervals (CIs) per tertile of polygenic risk score
were calculated. After analyzing multivariate Cox-proportional
hazard model, Harrell’s C index was calculated to evaluate
predictive accuracy of polygenic risk score model [20]. In addition,
4-fold cross-validation method was used to appraise the internal
validity of our model; the entire data set was randomly partitioned
into 4 equal size subsets. Of the 4 subsets, 3 subsets were used as
training data, and a remaining single subset was retained as the
validation data for testing the model. Significantly associated SNPs
with prognosis of breast cancer were firstly estimated in training
set and then Harrell’s C index was estimated based on those SNPs
in validation set. The cross-validation process was then repeated 4
times. The summary of these 4 Harrell’s indices was assessed by
fixed-effect model meta-analysis.
The GSEA-SNP method was used to reveal the biological
function of the SNPs which were significantly related to breast
cancer prognosis [21]. Pathway information was obtained from
the Molecular Signatures Database (MSigDB) which collected
annotated gene sets from the following online databases; BioCarta,
KEGG, Pathway Interaction Database, Reactome, SigmaAldrich,
Signaling Gateway, Signal Transduction KE, and SuperArray. In
addition, gene sets that have been extracted from experimental
studies were included in the database. The curated gene sets were
downloaded from MSigDB (version 4.0, C2). Because there was a
chance of the biological pathway being narrowly defined, each
pathway was set up to contain at least three genes in the following
analyses. The names of gene sets were described with ‘brief
description’ rather than ‘standard name’ which is available on the
Figure 2. Overview of inclusion and exclusion criteria in systematic review.
doi:10.1371/journal.pone.0103593.g002
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GSEA web (http://www.broadinstitute.org/gsea/index.jsp), be-
cause standard name equivocally explained function of gene set.
The statistical significance of the effects was estimated with a p-
value less than 0.05 in both multivariate Cox-proportional hazard
model by individual variants and polygenic risk score models and
0.1 in GSEA-SNP. The SAS statistical software package version
9.3, PLINK program version 1.07, and R 2.15.1 packages
(GenABEL), STATA statistical software version 12.0 were used
for the analyses.
Systematic review
Previous studies conducting analyses to find associations
between immunity-related genetic factors and the prognosis of
cancer in the epidemiologic field were selected for Jan 2000
through Dec 2013 (Figure 2). Available studies for systematic
review were searched in the PubMed and EMBASE database with
a set of keywords that delineated breast cancer as well as other
cancers, immune, genetic factors, and survival; cancer AND
immune AND polymorphism AND survival. Abstracts were
reviewed to identify reports examining associations between
immunity-related genetic factors and clinical outcomes including
recurrence and death. Literatures were excluded in the following
circumstances; review paper, studies unrelated with genomic
epidemiology, using SNPs located in non-immune related genes,
duplicated in both databases, with no survival or recurrence data
reported for survival analysis and no hazard ratios (HRs) reported
which were estimated with the Cox-proportional hazard model for
the associations of immunity-related genetic factors with cancer
outcomes (Figure 2). In cases of duplication between both
databases, the studies were deemed to have been searched in the
PubMed database. The following data were extracted from each
eligible study from the literature; disease site, authors, genes
Table 1. Characteristic of study participants.
Characteristics No. of patients (%) No. of events (%) Pa HRb (95% CI) Pb
Total 107 (100.0) 20 (100.0)
Age (Mean 6 SD) 50.668.2 52.5610.6 0.60
,50 54 (50.5) 11 (55.0) 1.00
$50 53 (49.5) 9 (45.0) 0.79 (0.33–1.91) 0.60
Body mass index (Mean 6 SD) 23.762.9 24.462.13 ,0.02
,21.4 (median) 30 (33.3) 1 (5.0) 1.00
$21.4 77 (66.7) 19 (95.0) 7.30 (0.98–54.61) 0.05
Family history 1.00
No 97 (90.7) 18 (90.0) 1.00
Yes 10 (9.3) 2 (10.0) 1.00 (0.23–4.37) 1.00
Educational level 0.46
#Middle school 30 (28.3) 4 (20.0) 1.00
High school 46 (43.4) 11 (55.0) 1.95 (0.62–6.13) 0.26
$College or university 30 (28.3) 5 (25.0) 1.27 (0.34–4.73) 0.72
Menopausal status 0.71
Premenopausal 62 (58.5) 11 (55.0) 1.00
Postmenopausal 44 (41.5) 9 (45.0) 1.18 (0.49–2.84) 0.72
Smoking status 0.10
Never 100 (93.5) 17 (85.0)
Ever 7 (6.5) 3 (15.0) 2.70 (0.78–9.17) 0.12
Alcohol consumption 0.66
Never 70 (65.4) 14 (70.0)
Ever 37 (34.6) 6 (30.0) 0.81 (0.31–2.10) 0.66
Estrogen receptor status 0.07
Positive 66 (62.3) 9 (45.0) 1.00
Negative 40 (37.7) 11 (55.0) 2.19 (0.90–5.28) 0.08
Progesterone receptor status 0.01
Positive 53 (50.5) 5 (25.0) 1.00
Negative 52 (49.5) 15 (75.0) 3.39 (1.23–9.37) 0.02
TNM stage ,0.01
0/I 48 (45.3) 4 (20.0) 1.00
II 40 (37.7) 7 (35.0) 2.20 (0.64–7.56) 0.21
III 18 (17.0) 9 (50.0) 8.54 (2.62–27.88) ,0.01
aLog rank test.
bUnivariate Cox-proportional hazard model.
doi:10.1371/journal.pone.0103593.t001
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Table 2. Associations between the genetic variations of immunity-related genes and breast cancer disease free survival in the
additive model (significance level, P,5.00E-02).
Gene Location SNP MAF HRa (95% CI) P
SOCS4 intronic rs1952438 0.04 11.99 (3.62–39.72) 4.84E-05
TSLP UTR5 rs2289278 0.15 4.25 (2.10–8.62) 5.99E-05
HGF intronic rs2074724 0.11 4.63 (2.18–9.87) 7.04E-05
IL-17C intronic rs2254073 0.15 4.24 (1.90–9.49) 4.31E-04
BCL2 intergenic rs9989529 0.19 3.80 (1.63–8.84) 1.98E-03
CCL2 intergenic rs17652343 0.08 4.57 (1.74–11.97) 2.01E-03
ITGB2 intronic rs2838727 0.04 6.57 (1.84–23.44) 3.70E-03
TRAF2 intergenic rs908831 0.14 3.79 (1.54–9.36) 3.79E-03
NBN downstream rs2142097 0.42 3.55 (1.48–8.49) 4.40E-03
SELE intergenic rs4656701 0.35 0.28 (0.11–0.71) 7.41E-03
CCR1 downstream rs3136671 0.19 3.05 (1.33–7.00) 8.47E-03
HGF intronic rs5745752 0.33 0.29 (0.11–0.73) 9.22E-03
IL-12A intergenic rs9811792 0.31 0.23 (0.08–0.71) 1.01E-02
MIF ncRNA_exonic rs1007888 0.41 2.39 (1.22–4.67) 1.11E-02
ITGB2-AS1 ncRNA_exonic rs2070946 0.12 2.98 (1.28–6.93) 1.11E-02
MIF ncRNA_intronic rs2000466 0.18 3.37 (1.32–8.60) 1.12E-02
ALOXE3 intronic rs3027215 0.07 3.17 (1.28–7.87) 1.27E-02
IFNAR2 intronic rs2073362 0.15 3.86 (1.33–11.17) 1.28E-02
XDH intergenic rs10490361 0.46 0.44 (0.23–0.84) 1.35E-02
CCL8 intergenic rs3138034 0.07 3.59 (1.29–9.96) 1.42E-02
SOCS2 intronic rs3782415 0.48 2.38 (1.18–4.83) 1.60E-02
DEF6 intronic rs6938946 0.34 2.26 (1.16–4.39) 1.68E-02
ABHD16A intronic rs2295663 0.10 2.55 (1.16–5.59) 1.93E-02
LBP intronic rs12624843 0.30 0.33 (0.13–0.84) 2.03E-02
IL-18 intergenic rs243908 0.33 3.59 (1.22–10.61) 2.05E-02
IL-10RB UTR3 rs1058867 0.32 2.62 (1.14–6.04) 2.33E-02
IL-6R intergenic rs11265608 0.04 4.15 (1.21–14.21) 2.36E-02
IRAK4 intronic rs4251460 0.11 2.78 (1.15–6.73) 2.38E-02
TRAF5 intronic rs6684874 0.29 0.29 (0.10–0.85) 2.46E-02
MIF ncRNA_intronic rs17004044 0.17 0.23 (0.06–0.83) 2.48E-02
XDH intronic rs1429372 0.38 0.43 (0.20–0.91) 2.70E-02
LMAN1 intronic rs12953981 0.41 0.41 (0.19–0.91) 2.74E-02
ALOXE3 intronic rs3027208 0.43 0.44 (0.21–0.91) 2.76E-02
CCL11 intergenic rs4795904 0.08 3.11 (1.13–8.56) 2.81E-02
IL-12B intergenic rs4921468 0.22 2.54 (1.10–5.87) 2.85E-02
IL-4R UTR3 rs8832 0.42 0.39 (0.17–0.91) 2.85E-02
IL-12A intergenic rs747825 0.15 0.10 (0.01–0.79) 2.90E-02
SCNN1A intronic rs3759324 0.36 2.10 (1.07–4.14) 3.03E-02
ITGB2 intronic rs1474552 0.23 0.26 (0.08–0.88) 3.06E-02
C6 intronic rs13168926 0.40 0.40 (0.18–0.92) 3.08E-02
FGF2 intergenic rs308447 0.08 2.89 (1.09–7.65) 3.25E-02
IL-10 intronic rs3021094 0.42 0.40 (0.17–0.93) 3.26E-02
SELE intergenic rs4656699 0.20 0.31 (0.11–0.92) 3.41E-02
STK19 intronic rs389883 0.26 1.96 (1.05–3.67) 3.46E-02
STAT4 intronic rs1031509 0.31 0.43 (0.19–0.94) 3.53E-02
NCF4 intronic rs2075938 0.39 2.17 (1.05–4.51) 3.66E-02
SLC2A11 intergenic rs1984309 0.39 0.44 (0.20–0.95) 3.68E-02
BPI intronic rs2275954 0.40 2.19 (1.05–4.59) 3.70E-02
TNFRSF1A intronic rs4149577 0.41 0.37 (0.14–0.94) 3.70E-02
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assessed, number of polymorphisms assessed, number of patients
and events including recurrence, death, follow-up period, type of
outcome, and covariates. Associations between polymorphisms
and the outcome of each cancer were recorded as HR with 95%
CI and adjustments. Because different nomenclatures and names
for polymorphisms were used in the studies, all polymorphisms
were named by RefSNP (rs) numbers. We followed the Preferred
Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) statement and checklist as a methodological template
for this review (Table S1).
Results
Table 1 shows the characteristics of the 107 patients including
20 patients who had the events. Among the 107 cases, BMI, PR
status, and TNM stage showed a significant association with the
prognosis on the DFS of breast cancer (P,0.05, log-rank test),
while there were no significant differences in age, family history of
breast cancer, educational level, menopausal status, smoking
status, alcohol consumption, and ER status.
The associations of immunity-related genetic factors on DFS of
breast cancer prognosis are presented in Table 2. Among 1,971
SNPs, 80 SNPs were significantly associated with the DFS of
breast cancer. The 62 SNPs were remained after excluding those
with high LD (r2.0.4) and 3 SNPs were still significant at FDR p-
value less than 0.05. The SNPs were rs1952438 in SOCS4 gene
(HR=11.99, 95% CI=3.62–39.72, P=4.84E-05), rs2289278 in
TSLP gene (HR=4.25, 95% CI=2.10–8.62, P=5.99E-05) and
rs2074724 in HGF gene (HR=4.63, 95% CI=2.18–9.87,
P=7.04E-05).
Figure 1 presents the Kaplan-Meier survival curve and
estimated HRs of breast cancer in groups defined by tertile
derived from the polygenic risk scores of the 107 patients with all
62 SNPs. The HR was significantly increased as the score
increased (p for trend= 0.01). The HR of women in the 3rd tertile
was 6.78 (95% CI= 1.48–31.06) compared to patients in the 1st
tertile of polygenic risk score. Table 3 shows the predictive
accuracy and validation results of polygenic risk score model. The
Harrell’s C index of total patients is 0.813, and summarized
Harrell’s C index of cross validation is 0.924.
In GSEA-SNP analysis, our results showed that 18 pathways
with 62 SNPs in 56 immunity-related genes had significant
association with the DFS of breast cancer at a p-value less than 0.1
(Table 4); set ‘Myc targets1’: targets of c-Myc identified by ChIP
on chip in cultured cell lines, focusing on E-box-containing genes;
high affinity bound subset (including BCL2 and NBN, P=0.04),
mitochondrial genes; based on literature and sequence annotation
resources and converted to Affymetrix HG-U133A probe sets
(including BCL2 and NBN, P=0.04), genes down-regulated in
T24 (bladder cancer) cells in response to the photodynamic
Table 2. Cont.
Gene Location SNP MAF HRa (95% CI) P
KLK15 upstream rs3745523 0.29 2.07 (1.04–4.12) 3.81E-02
BCL2 intronic rs12458289 0.28 2.27 (1.04–4.96) 4.00E-02
MBL2 intergenic rs11003134 0.20 8.09 (1.08–60.37) 4.16E-02
BCL10 intergenic rs6693365 0.30 2.36 (1.03–5.39) 4.18E-02
SELE intronic rs3917412 0.28 2.13 (1.03–4.40) 4.21E-02
CD180 intergenic rs6890674 0.15 2.27 (1.03–5.02) 4.29E-02
MAL intronic rs3113002 0.35 0.45 (0.21–0.98) 4.30E-02
AICDA UTR3 rs11046349 0.12 2.81 (1.03–7.69) 4.44E-02
C1QA intronic rs2935542 0.14 2.29 (1.02–5.13) 4.49E-02
IRF4 intergenic rs11242867 0.29 2.16 (1.02–4.61) 4.50E-02
IL-8 intergenic rs4694178 0.40 0.48 (0.23–0.99) 4.61E-02
MASP1 intronic rs3105782 0.15 2.30 (1.01–5.24) 4.70E-02
MUC2 intergenic rs4077757 0.03 3.88 (1.01–14.90) 4.80E-02
aMultivariate Cox proportional hazard model adjusted for age, estrogen receptor status, progesterone receptor status and TNM stage.
doi:10.1371/journal.pone.0103593.t002
Table 3. Harrell’s C index for polygenic risk score estimated by 4-fold cross-validation.
Group No. of SNPs in CV set Harrell’s C index Standard error (95% CI)
All 0.813 0.48 (0.72–0.91)
CV set1 25 0.885 0.09 (0.70–1.07)
CV set2 40 0.910 0.06 (0.78–1.04)
CV set3 32 0.940 0.03 (0.88–1.00)
CV set4 36 0.909 0.04 (0.82–1.00)
Summarya 0.924 0.02 (0.88–0.97)
aThe summary of Harrell’s C index for 4 test sets calculated by fixed-effect meta-analysis.
doi:10.1371/journal.pone.0103593.t003
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therapy (PDT) stress (including BCL2 and CCL2, P=0.04), genes
transiently induced only by the second pulse of EGF in 184A1 cells
(mammary epithelium) (including IRF3, TRAF5, KLK15 and
IL5R, P=0.02).
Table 5 showed 30 studies resulted from systematic review for
survival analyses estimating effects of immune-related genetic
factors on various cancers. In the studies, eighty eight SNPs in 58
immunity genes were significantly associated with the prognosis of
cancer patients (Table 6). In those results, there were 29 genes
overlapped in both our study and previous studies, but no SNPs
overlapped. Among them, IL-6R, IL-8, IL-10RB, IL-12A, and
IL-12B was significantly associated with the prognosis of cancer
consistent to our finding.
Discussion
In this study, we found that the rs1952438 in the suppressors of
cytokine signaling (SOCS4) gene, rs2289278 in the thymic stromal
lymphopoietin (TSLP) gene and rs2074724 in the hepatocyte
growth factor (HGF) gene were highly associated with a poor
prognosis of breast cancer. Moreover, the polygenic risk score
model with genetic variations of immunity-related genes showed
that the hazard of DFS of patients was significantly increased as
high-risk alleles accumulated. In the GSEA-SNP analysis, 18
pathways significantly affected breast cancer prognosis.
The rs1952438 is located in the intron region of SOCS4 gene.
SOCS family are rapidly induced by activated STATs and
negatively regulate JAK/STAT pathway by a classical feedback
loop [22]. Furthermore, other signal molecules such as FAK, IRS,
p65, GR which are related with carcinogenesis, are regulated by
SOCS proteins [23–27]. In addition, there are several previous
study which reported that people who have higher expression level
of SOCS4 are likely remained disease free status compared to
those who developed recurrence [28]. In the view of previous
studies which explain functional importance of SOCS4 and results
of present study, it might be assumed that rs1952438 is associated
with poorer prognosis of breast cancer by declining expression
level of SOCS4.
The rs2289278 is found in intron 2 of the long-form of TSLP
and in the 59 untranslated region of the short-form of TSLP [29].
TSLP is a member of the IL-2 cytokine family and a distant
paralog of IL-7. TSLP may have an important role in tumor
progression by activating CD4+ T cells, inducing the expressing of
OX40L in dendritic cells (DCs), and producing Th2-type
cytokines and B-cell growth factor [30]. A recent study has shown
that breast cancer cells have high expression levels of TSLP,
indicating that the TSLP may be critical in the development of
breast cancer [31]. It is that high expression level of TSLP in
cancer increases the Th2 level [30]. Furthermore, Th2 cytokines
promote disease progres-sion through the increased survival of
cancer cells, M2 macrophage differentia-tion, and fibrosis [31,32].
Thus, TSLP may be an important factor of breast tumor
progression and the prognosis of a patient.
The rs2074724 is located in the intron of HGF. HGF is known
to activate angiogenesis of tumors as well as cell-cell interactions,
matrix adhesion, migration, invasion [33]. Moreover, breast
cancer patients with a high HGF concentration had a significantly
poor prognosis when compared to those with a low HGF
concentration [34]. Therefore, HGF level was found to be the
most important independent factor in predicting the prognosis of
breast cancer.
In the GSEA-SNP analysis, there are 18 significant pathways;
among these pathways, gene set from Kyng et al [35] which
included rs1952438 in SOCS4 gene and rs2074724, and
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Table 6. Genes that have significant SNPs of each study in the review of previous studies.
Gene SNP Primary endpointa HR (95% CI) P Type of cancerb Ref
C7 rs324058 EFS 1.66 (0.87–3.17) 0.04 Lymphoma [69]
C9 rs1421094 EFS 0.54 (0.32–0.90) 0.02 Lymphoma [69]
CCR5 rs1800940 OS 0.73 (0.53–1.00) - Lymphoma [68]
CD46 rs2466571 EFS 1.49 (0.86–2.61) 0.05 Lymphoma [69]
CD55 rs2564978 EFS 0.52 (0.30–0.88) ,0.01 Lymphoma [69]
CD80 rs13071247 OS 1.73 (1.26–2.39) ,0.01 Ovarian cancer [72]
rs7804190 OS 1.14 (1.06–1.23) ,0.01 Ovarian cancer [72]
CFH rs3766404 EFS 2.25 (1.31–3.87) ,0.01 Lymphoma [69]
rs1329423 EFS 0.49 (0.29–0.38) ,0.01 Lymphoma [69]
CFHR1 rs436719 EFS 0.57 (0.34–0.96) 0.03 Lymphoma [69]
CFHR5 rs6694672 EFS 2.63 (1.41–4.92) ,0.01 Lymphoma [69]
CLU rs3087554 EFS 0.46 (0.21–1.00) 0.05 Lymphoma [69]
COX-2 rs689466 OS 0.58 (0.39–0.86) 0.01 NSCLC [58]
ERCC2 rs238406 OS 1.64 (1.08–2.50) 0.02 Esophageal cancer [75]
rs238406 PFS 1.76 (1.17–2.66) 0.01 Esophageal cancer [75]
rs1799793 BCSS 1.90 (1.06–3.26) 0.04 Breast cancer [53]
rs1799793 EFS 0.23 (0.05–0.99) 0.01 Osteosarcoma [74]
FasL rs763110 OS 1.46 (1.13–1.87) ,0.01 NSCLC [60]
rs763110 RFS 1.71 (1.33–2.21) ,0.01 NSCLC [60]
GATA3 rs10905278 OS 1.82 (1.31–2.53) ,0.01 Pancreatic cancer [73]
IFNAR1 rs2257167 EFS 0.74 (0.55–1.00) 0.05 NSCLC [63]
IFNGR1 rs1327474 OS 0.69 (0.50–0.94) 0.02 Colorectal cancer [56]
rs9376267 OS 1.37 (1.09–1.73) 0.01 Colorectal cancer [56]
IFNGR2 rs2834211 OS 1.32 (1.01–1.72) 0.04 Colorectal cancer [56]
rs2834213 OS 2.04 (1.16–3.57) 0.01 Colorectal cancer [56]
IFNW1 rs10964859 OS 1.80 (1.02–3.16) 0.04 Melanoma [71]
IL-10RB rs8128184 EFS 1.59 (1.11–2.29) 0.01 NSCLC [63]
IL-12A rs2243148 EFS 1.28 (1.03–1.58) 0.03 NSCLC [63]
IL-12B rs3212227 OS 1.83 (1.09–3.06) ,0.01 Lymphoma [42]
IL-13 rs1295683 EFS 1.39 (1.03–1.87) 0.03 NSCLC [63]
IL-1A rs3783546 OS 2.07 (1.28–3.36) 0.02 Colorectal cancer [57]
rs1800587 OS 1.90 (1.26–2.87) ,0.01 Lymphoma [70]
IL-1B rs1143623 OS 1.37 (1.09–1.72) 0.01 Colorectal cancer [57]
rs1143627 OS 0.50 (0.30–1.00) 0.04 Myeloma [77]
IL-1RN rs454078 OS 1.93 (1.11–3.34) 0.03 Lymphoma [42]
IL-2 rs2069763 OS 1.43 (1.15–3.82) - Breast cancer [13]
rs2069762 OS 1.80 (1.06–3.05) 0.01 Lymphoma [42]
IL-21 rs12508721 OS 0.45 (0.30–0.67) ,0.01 Breast cancer [12]
IL-23R rs6682925 OS 1.34 (1.05–1.70) - NSCLC [59]
IL-3 rs181781 OS 2.47 (1.11–5.53) 0.03 Colorectal cancer [57]
IL-5 rs2069807 OS 4.56 (1.98–10.5) ,0.01 Lymphoma [70]
rs2069818 OS 5.58 (1.66–18.6) 0.01 Lymphoma [42]
IL-5R rs11713419 OS 6.60 (2.42–18.02) - NSCLC [59]
IL-6 rs1800796 OS 0.42 (0.23–0.77) - Lymphoma [68]
rs1800797 DFS 1.60 (1.09–2.35) 0.02 Breast cancer [14]
IL-6R rs4240872 EFS 0.75 (0.59–0.95) 0.02 NSCLC [63]
IL-8 rs4073 OS 2.14 (1.26–3.63) - Lymphoma [42]
rs2227307 OS 1.90 (1.12–3.22) - Lymphoma [42]
rs2227306 OS 1.96 (1.07–3.28) - Lymphoma [42]
rs12506479 EFS 1.32 (1.08–1.62) 0.01 NSCLC [63]
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rs5745752 in HGF gene is described that environmental stress
such as 4-nitroquinoline-1-oxide (4NQO) elicited DNA damage
specific gene expression changes of up to 10. In short, it can be
expected that those SNPs included in the pathway can up-regulate
breast cancer progression and result in poor prognosis by
Table 6. Cont.
Gene SNP Primary endpointa HR (95% CI) P Type of cancerb Ref
IL-8RB rs1126579 OS 1.61 (1.05–2.46) 0.02 Colorectal cancer [57]
rs1126580 OS 2.11 (1.28–3.50) ,0.01 Lymphoma [70]
IRF2 rs12504466 OS 1.51 (1.14–1.99) ,0.01 Colorectal cancer [56]
rs13116389 OS 1.38 (1.09–1.75) 0.01 Colorectal cancer [56]
rs2797507 OS 0.77 (0.61–0.98) 0.03 Colorectal cancer [56]
rs3775582 OS 0.67 (0.50–0.89) 0.01 Colorectal cancer [56]
rs7655800 OS 1.33 (1.04–1.70) 0.02 Colorectal cancer [56]
rs793801 OS 1.39 (1.01–1.91) 0.04 Colorectal cancer [56]
rs1425551 OS 1.50 (1.03–2.18) 0.04 Colorectal cancer [56]
rs3756094 OS 0.36 (0.20–0.66) ,0.01 Colorectal cancer [56]
rs3822118 OS 1.47 (1.08–2.01) 0.02 Colorectal cancer [56]
rs807684 OS 0.30 (0.14–0.66) ,0.01 Colorectal cancer [56]
rs1044873 OS 1.32 (1.04–1.68) 0.03 Colorectal cancer [56]
rs305083 OS 1.31 (1.04–1.65) 0.02 Colorectal cancer [56]
IRF6 rs2013196 OS 1.29 (1.02–1.63) 0.03 Colorectal cancer [56]
LRRC32 rs3781699 OS 2.32 (1.45–3.71) ,0.01 Ovarian cancer [72]
rs7944357 OS 2.04 (1.34–3.10) ,0.01 Ovarian cancer [72]
MBL2 rs7096206 OS 0.55 (0.42–0.73) ,0.01 NSCLC [65]
MET rs11762213 RFS 1.86 (1.17–2.95) 0.01 Renal cell cancer [67]
NFKB rs7157810 OS 1.43 (1.16–1.75) ,0.01 Pancreatic cancer [73]
NOD2 rs9302752 OS 3.19 (2.04–4.34) - Bladder cancer [66]
NOS3 rs1799983 OS 1.39 (1.14–1.70) ,0.01 Pancreatic cancer [73]
REG4 rs2994809 DFS 2.00 (1.18–3.39) 0.01 Colorectal cancer [54]
rs2994811 OS 1.35 (1.02–1.78) 0.03 Colorectal cancer [54]
RGS1 rs10921202 OS 2.93 (1.77–4.84) ,0.01 Ovarian cancer [72]
RIPK1 rs2326173 OS 1.44 (1.20–1.74) ,0.01 Pancreatic cancer [73]
SOCS3 rs8064821 OS 0.65 (0.49–0.87) ,0.01 Pancreatic cancer [73]
STAT1 rs12693591 OS 0.68 (0.55–0.86) ,0.01 Pancreatic cancer [73]
TGF-b1 rs10469 OS 1.46 (1.01–2.11) 0.04 NSCLC [61]
rs1982073 DMFS 1.59 (1.01–2.50) 0.05 NSCLC [61]
rs1982073 DFS 3.23 (1.19–8.77) 0.02 HNSCC [76]
rs1800469 OS 0.46 (0.25–0.87) 0.02 NSCLC [62]
TGFBR1 rs10512263 EFS 0.59 (0.37–0.94) 0.03 NSCLC [63]
rs868 EFS 1.28 (1.01–1.61) 0.04 NSCLC [63]
TGFBR2 rs2043136 EFS 0.74 (0.58–0.95) 0.02 NSCLC [63]
TLR1 rs5743551 OS 0.78 (0.62–0.97) - NSCLC [59]
TLR10 rs4129009 OS 0.49 (0.18–0.80) - Bladder cancer [66]
TLR3 rs3775291 OS 1.93 (1.14–3.28) - Colorectal cancer [55]
rs3775291 OS 1.37 (1.09–1.73) - NSCLC [59]
TLR4 rs11536889 OS 1.38 (1.09–3.12) 0.02 Breast cancer [11]
TNFRSF10B rs11785599 EFS 1.41 (1.16–1.70) ,0.01 NSCLC [63]
TNFRSF1B rs1061622 OS 0.38 (0.15–0.94) 0.04 NSCLC [64]
TNFRSF4 rs3753348 OS 3.41 (1.65–7.05) ,0.01 Ovarian cancer [72]
aEFS, event free survival; OS, overall survival; RFS, relapse free survival; DFS, disease free survival; DMFS, distant metastasis-free survival; BCSS, breast cancer specific
survival.
bDLBCL, diffuse large B-cell lymphoma; NSCLC, non-small cell lung cancer; FL, follicular lymphoma; HNSCC, head and neck squamous cell carcinoma.
doi:10.1371/journal.pone.0103593.t006
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influencing on environmental response, although there are not
precise result in this assumption.
‘Myc tagets1’ gene set from Benporath et al [36] which included
rs12458289 and rs9989529 in BCL2 gene, and rs2142097 in NBN
gene is shown as the most significant gene set. Benporath et al
describe that targets of Nanog, Oct4, Sox2 and c-Myc are more
frequently associated in poorly differentiated tumors than in well-
differentiated tumors. c-Myc is well known to directly regulate the
expression of NBN gene involved in DNA double-strand break
repair and can result in chromosomal instability, cellular
proliferation defects leading to increased more aggressive and
metastatic tumor latency [37,38]. BCL2 and c-Myc are known to
make the negative feedback loop in breast cancer cell line [39].
Taking all these consideration of both Benporath et al and results
of present study to account, it is can be deduced that rs12458289,
rs9989529, and rs2142097 might be associated with the prognosis
of breast cancer by interacting with c-MYC gene.
To support the indirectly functional effects of our results, we
attempted to find potential functional SNPs in SOCS4, HGF,
TSLP and genes included in GSEA-SNP using UCSC database
[40] and checked the LD between the potential functional SNPs
and our findings. Table S2 show the functional SNPs studied in
this study and functional SNPs in LD with those SNPs, generally
to affect histone modification, DNA methylation, and binding
affinity of several transcription factors located in 59UTR or
39UTR. For example, transcription activity of IL-8 is influenced
by rs4073 which located in promoter region of IL-8 [41] and the
variant increased the risk of mortality in follicular lymphocytic
leukemia by increasing production of IL-8 [42]. As a result, it is
possibly anticipated that those potential SNPs may influence to
breast cancer prognosis by regulating the epigenetic and
transcriptional pathway.
Several previous reports have evaluated the associations of
immunity gene polymorphism and breast cancer prognosis [11–
14]. They suggested that the variants of ERCC2, TLR4, IL-2, IL-
6, and IL-21 genes had associations with breast cancer prognosis
respectively. However, those genes were not replicated in present
study. In the other types of cancer studies, IL-6R, IL-8, IL-10RB,
IL-12A, and IL-12B genes were consistently associated with
cancer prognosis between our study and theirs. However, there
were few consistent SNPs with cancer prognosis in our review of
the literature, which may result from various cancer targets,
different ethnicities, and different prognostic factors in the models
and statistical power.
In this study, there are several limitations including a small
sample size and absence of an external validation study. Since the
power of this study was low to detect accurate results, the results of
this study are carefully interpreted, although the significance levels
of top 3 SNPs passed the FDR test with significance (p,0.05) and
the internal validity was confirmed by the cross-validation. In
addition, polygenic risk score model and GSEA-SNP are
conducted with whole significant SNPs which include insignificant
SNPs at FDR p-value greater than 0.05. Tag SNPs selected based
on the data of a Caucasian population and lack of breast cancer
subtype information were also limitations of this study. In the
systematic review-level, the summary measure and synthesis of the
results were not calculated because various genes and the
variations related to immune response were the focus. However,
the strength of this study is that lots of genetic factors in immune-
related genes were covered at once. Moreover, it attempted to
apply the candidate gene approach to cover the pathway of
immunity-related genetic factors with breast cancer prognosis in
Asian women.
In conclusion, our study found that common variants in the
SOCS4, TSLP and HGF genes might be related with breast
cancer prognosis in Korean women. Hazard of DFS in patients
was significantly increased when high-risk alleles were accumulat-
ed. Therefore, our results suggest that genetic polymorphisms in
immunity-related genes have relevance to breast cancer prognosis
among Korean women. Further large-scale functional studies are
needed to confirm our findings.
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